Aptorum Group Limited (NASDAQ:APM) Sees Large Decrease in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 8,693 shares, a drop of 24.8% from the February 26th total of 11,553 shares. Based on an average daily volume of 21,427 shares, the short-interest ratio is currently 0.4 days. Approximately 0.4% of the company’s stock are sold short.

Aptorum Group Price Performance

NASDAQ APM opened at $0.93 on Friday. Aptorum Group has a 12 month low of $0.65 and a 12 month high of $4.47. The stock’s fifty day moving average price is $0.87 and its 200-day moving average price is $1.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aptorum Group in a report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.